Skip to content
OpenCapital
Get started

ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q4 2024 Annual earnings

Reported March 25, 2025 · Before market open

Revenue$5.0MDiluted EPS-$3.99Miss by $3.07
EPS estimate-$0.92

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$15.0M
EPS estimate-$0.89

Versus estimates

Revenue

Q1 2025$10.0MBeat by $8.8M
Q4 2024$5.0M

Diluted EPS

Q1 2026-$1.46Beat by $0.01Q4 2025-$1.10Miss by $0.10Q3 2025-$1.22Miss by $0.35Q2 2025-$1.25Miss by $0.23Q1 2025-$0.80Beat by $0.31
Q4 2024-$3.99Miss by $3.07

Ask the moment ProShares UltraPro Short NASDAQ Biotechnology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ProShares UltraPro Short NASDAQ Biotechnology report Q4 2024 earnings?
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q4 2024 earnings on March 25, 2025 before market open.
What were ProShares UltraPro Short NASDAQ Biotechnology's Q4 2024 revenue and EPS?
ProShares UltraPro Short NASDAQ Biotechnology reported revenue of $5.0M and diluted EPS of $-3.99 for Q4 2024.
Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.92 by $3.07.
Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-002631) directly on SEC EDGAR. The filing index links above go to sec.gov.